Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
暂无分享,去创建一个
Jim A. Julian | Zsolt Gabos | Timothy J. Whelan | Alexander V. Louie | M Wierzbicki | Sameer Parpia | Anand Swaminath | Vijayananda Kundapur | T. Whelan | A. Louie | M. Wierzbicki | E. Kurien | T. Tsakiridis | A. Bujold | Z. Gabos | E. Chan | J. Julian | Gordon Okawara | S. Faria | Edith Filion | A. Swaminath | K. Cline | James R. Wright | Theodoros Tsakiridis | Alexis Bujold | Naseer Ahmed | Khalid Hirmiz | Elizabeth Kurien | Sergio Faria | Timothy Owen | Elaine Wai | Kevin Ramchandar | Elisa K. Chan | K. Cline | N. Ahmed | E. Filion | E. Wai | S. Parpia | V. Kundapur | G. Okawara | K. Ramchandar | T. Owen | K. Hirmiz
[1] M. Corradetti,et al. Central-airway necrosis after stereotactic body-radiation therapy. , 2012, The New England journal of medicine.
[2] David J Sugarbaker,et al. Surgery for early stage non-small cell lung cancer. , 2003, Seminars in surgical oncology.
[3] L V Rubinstein,et al. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1995, The Annals of thoracic surgery.
[4] Do-Hoon Kim,et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] E. Vokes,et al. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Suresh Senan,et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. , 2012, The Lancet. Oncology.
[7] M. Iannuzzi,et al. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. , 2005, Chest.
[8] C B Begg,et al. Racial differences in the treatment of early-stage lung cancer. , 1999, The New England journal of medicine.
[9] Lech Papiez,et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Stereotactic body radiotherapy for stage I NSCLC: the challenge of evidence-based medicine. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] P. Xia,et al. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity. , 2014, International journal of radiation oncology, biology, physics.
[12] Masahiro Hiraoka,et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. , 2005, International journal of radiation oncology, biology, physics.
[13] J. Greenland,et al. Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. , 2014, Journal of the National Cancer Institute.
[14] Jan Nyman,et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] Lech Papiez,et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. , 2009, International journal of radiation oncology, biology, physics.
[16] S. Senan,et al. Outcomes of Hypofractionated High‐Dose Radiotherapy in Poor‐Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] Aaron Ward,et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[18] B. Slotman,et al. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[19] E. Yorke,et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. , 2016, Practical radiation oncology.
[20] A. Bezjak,et al. The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).
[21] Andrea Bezjak,et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.